Last reviewed · How we verify
mOPV type 2
mOPV type 2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 through mucosal and systemic immunity.
mOPV type 2 is a live attenuated oral polio vaccine that stimulates immune responses against poliovirus type 2 through mucosal and systemic immunity. Used for Poliomyelitis prevention (poliovirus type 2), Immunization against poliovirus type 2 in routine childhood vaccination programs.
At a glance
| Generic name | mOPV type 2 |
|---|---|
| Also known as | GSK mOPV type 2 |
| Sponsor | University of Chile |
| Drug class | Live attenuated vaccine |
| Target | Poliovirus type 2 |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
mOPV2 (monovalent oral polio vaccine type 2) contains a weakened live poliovirus type 2 strain that replicates in the intestinal tract, triggering both mucosal IgA antibodies and systemic IgG responses. This oral administration route provides intestinal immunity while also generating systemic protection against poliovirus type 2 infection and disease.
Approved indications
- Poliomyelitis prevention (poliovirus type 2)
- Immunization against poliovirus type 2 in routine childhood vaccination programs
Common side effects
- Vaccine virus shedding in stool
- Mild gastrointestinal symptoms
- Vaccine-associated paralytic poliomyelitis (VAPP)
Key clinical trials
- Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh (PHASE2)
- Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama (PHASE2)
- Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mOPV type 2 CI brief — competitive landscape report
- mOPV type 2 updates RSS · CI watch RSS
- University of Chile portfolio CI